## PHAFIMA DENO PLE

## FINANCIAL STATEMENT FOR HALF YEAR 2022

 STATEMENT OF COMPREHENSIVE INCOME| DESCRIPTION | Jan-Jun | Jan-Jun | Jan-Dec |
| :---: | :---: | :---: | :---: |
|  | 2022 | 2021 | 2021 |
|  | N'000 | N'000 | N'000 |
| Turnover | 252,810 | 311,733 | 503,548 |
| Cost of sales | $(207,180)$ | $(216,837)$ | $(104,193)$ |
| Gross Margin | 45,630 | 94,896 | 93,355 |
| Other Operating Income | 25,970 | 6,260 | 61,438 |
| Other Operating gains (losses) | - | - |  |
|  | 71,600 | 101,156 | 154,793 |
| Selling and distribution expenses | $(22,170)$ | $(21,909)$ | $(22,092)$ |
| Administration expenses | $(93,510)$ | $(86,541)$ | $(198,357)$ |
| Impairment of Asset | - | - | - |
| Operating Profit/(Loss) | $(44,080)$ | $(7,294)$ | $(65,656)$ |
| Finance cost | $(4,910)$ | (975) | $(2,833)$ |
| Loss after Finance cost | $(48,990)$ | $(8,269)$ | 68,489) |
| Taxation | - | - | $(1,298)$ |
| Loss from Continuing Operation | $(48,990)$ | $(8,269)$ | $(69,787)$ |
| Profit(loss) from discontinuing Operation |  |  |  |
| Profit (loss) for the period | $(48,990)$ | $(8,269)$ | $(69,787)$ |
| Per share data (50 kobo ordinary share): |  |  |  |
| Profit per share-Kobo | (22.6) | (3.8) | (32.16) |

(Note: the number of shares as at June '22, 217million shares)

## PHARTMA <br> DEMD PLE

## FINANCIAL STATEMENT FOR HALF YEAR 2022

## STATEMENT OF FINANCIAL POSITION

Property, plant and equipment
Deferred TaxAssets
Investment property Intangible Assets
Investments accounted for using the equity method
Financial assets
Non-current asset held for sale and disposal groups

Total Non Current Assets
Inventories
Debtors and Other Receivables
Cash and cash equivalents
Total Current Assets

Provisions (Employee Benefits)
Trade and Other Payables
Current Financial liabilities
Current Tax Liabilities
Total Current Liabilities
Non-Current Financial liabilities
Deferred Tax Liabilities
Total Non-Current Liabilities
Working Capital
Net Assets

Non Controlling Interest
Attributable to Owners of the Company

| As At Jun | As At Dec | \%Change | Beginning of |
| :---: | :---: | :---: | :---: |
| 2022 | 2021 |  | Prior Year |
| N'000 | N'000 |  | N'000 |
| 2,022,225 | 2,056,472 | 23\% | 1,663,711 |
| - |  |  |  |
| - |  |  |  |
| - |  |  |  |
| - | - |  |  |
| - | - |  |  |
| 2,022,225 | 2,056,472 | 23\% | 1,663,711 |
| 152,417 | 182,383 | -22\% | 174,102 |
| 75,764 | 57,712 | 5\% | 70,835 |
| 11,657 | 38,754 | -68\% | 108,408 |
| 239,838 | 278,849 | -21\% | 353,345 |


| 197,577 | 197,827 | $0 \%$ | 200,261 |
| ---: | ---: | ---: | ---: |
| 584,339 | 630,357 | $-5 \%$ | 674,519 |
| 35,000 | 13,000 | $169 \%$ | 13,336 |
| 124,736 | 124,736 | $0 \%$ | 124,602 |
| $\mathbf{9 4 1 , 6 5 2}$ | $\mathbf{9 6 5 , 9 2 0}$ | $-1 \%$ | $\mathbf{1 , 0 1 2 , 7 1 8}$ |
| - | - | $0 \%$ | - |
| 61,556 | 61,556 | $241 \%$ | 18,071 |
| $\mathbf{6 1 , 5 5 6}$ | $\mathbf{6 1 , 5 5 6}$ | $241 \%$ | $\mathbf{1 8 , 0 7 1}$ |
| $(701,814)$ | $(687,071)$ | $8 \%$ | $(659,373)$ |
| $\mathbf{1 , 2 5 8 , 8 5 5}$ | $\mathbf{1 , 3 0 7 , 8 4 5}$ | $\mathbf{2 9 \%}$ | $\mathbf{9 8 6 , 2 6 7}$ |

## PHAPMA DEMO PLE

## FINANCIAL STATEMENT FOR HALF YEAR 2022

## STATEMENT OF CHANGE IN EQUITY

|  | Share | Capital | Revaluation | Retained | Total |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Capital | Reserve | Surplus | Earnings | Equity |
| Balance as at Beginning of the Prior Year | 108,466 | 380,009 | 1,365,223 | $(937,218)$ | 1,307,845 |
| Changes in Equity Current year: |  |  |  |  | - |
| Refund on Right Issue |  | - |  |  | - |
| Revaluation Surplus (net of tax) |  |  | - |  | - |
| Dividend Paid | - | - | - |  |  |
| Total Comprehensive Income | - | - | 391,365 | $(48,990)$ | 342,375 |
| Balance as at End of the Prior Year | 108,466 | 380,009 | 1,756,588 | $(986,208)$ | 1,650,220 |
| Changes in Equity Current year: |  |  |  |  |  |
| Movement during the year |  | - |  | - | - |
| Revaluation Surplus (net of tax) |  |  |  |  | - |
| Interim Dividend Paid |  |  |  | - | - |
| Total Comprehensive Income | - | - | - | $(69,787)$ | $(69,787)$ |
| Balance as at End of the Period | 108,466 | 380,009 | 1,756,588 | (1,055,995) | 1,580,433 |

## PHARMA DEMD pLe

## FINANCIAL STATEMENT FOR HALF YEAR 2022

## STATEMENT OF CASH FLOW

| Cash Flow from Operating Activities |  |  |  |
| :---: | :---: | :---: | :---: |
| Operating Cash Flow before Working Capital Changes | $(48,890)$ | $(43,477)$ | 12\% |
| Net Cash Generated from Operating Activities | $(48,890)$ | $(43,477)$ | 12\% |
| Net Cash provided (used) by investing activities | (207) | $(25,841)$ | -99\% |
| Cash Flow from Financing Activities | 22,000 | (336) | -6648\% |
| Net Increase/Decrease Cash and Cash Equivalent | $(27,097)$ | $(69,654)$ | -61\% |
| Cash Equivalent Beginning of the Year | 38,754 | 108,408 | -64\% |
| Effect of exchange rate movement on cash balances | - | - | 0\% |
| Total Cash at the end of the period | 11,657 | 38,754 | -70\% |

